FormulaFolio Investments’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
$17K Hold
150
0.01% 198
2021
Q1
$17K Sell
150
-86,548
-100% -$9.26M 0.01% 197
2020
Q4
$9.29M Buy
86,698
+60,251
+228% +$5.79M 0.19% 92
2020
Q3
$2.32M Buy
26,447
+1,909
+8% +$180K 0.09% 89
2020
Q2
$2.41M Buy
24,538
+392
+2% +$34.5K 0.1% 81
2020
Q1
$1.84M Sell
24,146
-1,979
-8% -$169K 0.1% 79
2019
Q4
$2.31M Buy
26,125
+2,731
+12% +$227K 0.08% 111
2019
Q3
$1.77M Buy
23,394
+1,997
+9% +$137K 0.07% 115
2019
Q2
$1.56M Sell
21,397
-1,293
-6% -$102K 0.07% 108
2019
Q1
$1.83M Buy
22,690
+6,036
+36% +$494K 0.08% 93
2018
Q4
$1.57M Hold
16,654
0.07% 99
2018
Q3
$1.57M Buy
16,654
+1,110
+7% +$105K 0.07% 99
2018
Q2
$1.44M Buy
15,544
+13,393
+623% +$1.31M 0.07% 95
2018
Q1
$204K Sell
2,151
-163
-7% -$17.9K 0.01% 259
2017
Q4
$224K Sell
2,314
-137
-6% -$12.9K 0.01% 234
2017
Q3
$218K Sell
2,451
-1,156
-32% -$88K 0.02% 208
2017
Q2
$262K Sell
3,607
-179
-5% -$12K 0.02% 183
2017
Q1
$247K Buy
+3,786
New +$238K 0.03% 186

Other funds holding ABBV

FormulaFolio Investments's ABBV Position: Q2 2021 in Review

FormulaFolio Investments held its AbbVie (ABBV) position steady in Q2 2021 at 150 shares worth $17K. The position accounts for 0.01% of the portfolio, ranked #198.

FormulaFolio Investments first reported a position in ABBV in Q1 2017 and has held it in 18 quarters since. The position peaked at $9.29M in Q4 2020. 2,676 funds tracked by Wall St. Rank hold ABBV as of Q2 2021.

  • FormulaFolio Investments held 150 shares of AbbVie worth $17K as of Q2 2021.
  • FormulaFolio Investments left its AbbVie share count unchanged in Q2 2021.
  • AbbVie made up 0.01% of FormulaFolio Investments's portfolio in Q2 2021, its #198 holding.
  • FormulaFolio Investments first reported a position in AbbVie in Q1 2017 and has held it in 18 quarters since.
  • FormulaFolio Investments's AbbVie position peaked at $9.29M in Q4 2020.
  • 2,676 funds tracked by Wall St. Rank held AbbVie as of Q2 2021.

Based on FormulaFolio Investments's 13F filing for Q2 2021, filed 28 Jul 2021.